SciSparc and NeuroThera report significant computational acceleration using CliniQuantum's GPU quantum-simulation platform for gene analysis.
Quiver AI Summary
SciSparc Ltd. announced that its subsidiary, NeuroThera Labs Inc., through its subsidiary CliniQuantum, has achieved significant computational advancements using a GPU-accelerated quantum-simulation platform. The platform demonstrated an approximate 16.8-fold increase in computational speed when analyzing a clinical dataset of gene expressions compared to traditional CPU methods. Specifically, it identified approximately 22.2 million correlated three-gene combinations from a dataset involving 11 patients and over 3,500 gene features. This analysis took about 0.5 hours on a GPU versus 8.4 hours on CPUs while maintaining results integrity. CliniQuantum plans to further develop these algorithms for more complex biomedical analyses and aims to transition from simulations to real quantum computing hardware. SciSparc focuses on developing cannabinoid-based pharmaceutical treatments for various conditions.
Potential Positives
- NeuroThera Labs’ GPU quantum-simulation platform demonstrated a significant computational acceleration, achieving an approximately 16.8-fold increase in performance compared to traditional CPU implementations, which highlights the potential for enhanced efficiency in data analysis.
- The successful identification of approximately 22.2 million correlated gene triplets from a challenging high-dimensional dataset indicates the algorithm's advanced capability in handling complex biomedical data, potentially positioning SciSparc favorably in the competitive pharmaceutical landscape.
- The ongoing development of advanced algorithms towards larger datasets and execution on quantum computing hardware suggests a commitment to innovation, which could foster long-term growth and advancements in drug development programs.
Potential Negatives
- The press release emphasizes the computational performance of CliniQuantum's algorithm but does not provide any evidence of clinical validity or potential utility of the identified gene combinations, which may raise concerns about the practical implications of the reported advancements.
- The reliance on a single machine with a specific GPU for performance metrics may appear overly narrow, potentially limiting the perceived robustness and applicability of the results in broader clinical and computational settings.
- The forward-looking statements section highlights significant risks and uncertainties, suggesting that the company's future performance may not align with the optimistic projections outlined in the release.
FAQ
What did SciSparc announce on October 7, 2026?
SciSparc announced that NeuroThera's CliniQuantum achieved significant computational acceleration using a GPU quantum-simulation platform.
How much computational acceleration was achieved?
CliniQuantum reported an approximately 16.8-fold acceleration using a single NVIDIA T4 Tensor Core GPU compared to CPU-only implementation.
What dataset was used for the evaluation?
The evaluation used a clinical gene-expression dataset comprised of 11 patients and 3,531 gene-expression features.
What types of treatments is SciSparc developing?
SciSparc is focused on cannabinoid pharmaceuticals, including treatments for Tourette syndrome, Alzheimer's disease, and autism spectrum disorder.
Where can I find more information about SciSparc's risks?
Detailed risk factors can be found in SciSparc’s Annual Report on Form 20-F, filed with the SEC on April 29, 2026.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$SPRC Insider Trading Activity
$SPRC insiders have traded $SPRC stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $SPRC stock by insiders over the last 6 months:
- ITSCHAK SHREM sold 462 shares for an estimated $4,620
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$SPRC Hedge Fund Activity
We have seen 7 institutional investors add shares of $SPRC stock to their portfolio, and 1 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- HRT FINANCIAL LP added 21,235 shares (+inf%) to their portfolio in Q2 2026, for an estimated $117,217
- JANE STREET GROUP, LLC added 16,496 shares (+inf%) to their portfolio in Q2 2026, for an estimated $91,057
- UBS GROUP AG added 1,372 shares (+43.6%) to their portfolio in Q2 2026, for an estimated $7,573
- JPMORGAN CHASE & CO added 211 shares (+inf%) to their portfolio in Q2 2026, for an estimated $1,164
- MORGAN STANLEY added 200 shares (+inf%) to their portfolio in Q2 2026, for an estimated $1,104
- STRATEGIC INVESTMENT SOLUTIONS, INC. /IL removed 133 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $734
- ROYAL BANK OF CANADA added 32 shares (+inf%) to their portfolio in Q2 2026, for an estimated $176
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Full Release
TEL AVIV, Israel, Oct. 07, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, that CliniQuantum Ltd. (“CliniQuantum”), NeuroThera’s majority owned subsidiary, reported that its Graphics Processing Unit- accelerated (“GPU”) quantum-simulation platform achieved an approximately 16.8-fold computational acceleration using a single machine with 64 cores (x86_64) and a single NVIDIA T4 Tensor Core GPU compared with the same 64-vCPU machine with only Central Processing Unit (“CPU”) implementation.
The evaluation used a real clinical gene-expression dataset comprising 11 patients and 3,531 gene-expression features, representing a challenging high-dimensional setting in which the number of biological variables greatly exceeds the number of patients.
The algorithm operated by CliniQuantum searched for correlated three-gene configurations across the dataset. The 3,531 genes generated 7,331,162,245 possible three-gene combinations. Using a predefined minimum correlation threshold, the algorithm identified approximately 22.2 million correlated gene triplets.
The analysis required approximately 8.4 hours using 64 vCPUs (virtual CPU), compared with approximately 0.5 hours when accelerated using a single NVIDIA T4 GPU, while producing the same qualifying gene-triplet results.
The benchmark was conducted on an AWS g4dn.16xlarge EC2 machine using an IBM Qiskit Aer GPU-based quantum simulation, with a NVIDIA T4 Tensor Core GPU. The benchmark was designed to evaluate computational performance and did not evaluate or establish the clinical validity, predictive value, or potential utility of any identified gene combinations.
CliniQuantum intends to continue advancing its algorithms toward the analysis of increasingly complex multi-feature configurations and larger biomedical datasets, while progressing its development pathway from simulation and validation toward execution on quantum computing hardware.
About SciSparc Ltd. (Nasdaq: SPRC):
The Company, through its majority-owned subsidiary NeuroThera, engages in clinical-stage pharmaceutical developments. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company, together with its majority-owned subsidiary NeuroThera, is currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome, for the treatment of Alzheimer's disease and agitation; and SCI- 210 for the treatment of autism spectrum disorder and status epilepticus. The Company, through NeuroThera, also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seed oil-based products on the Amazon.com Marketplace.
About NeuroThera Labs Inc.
NeuroThera is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations.
Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc uses forward-looking statements when it discusses the potential benefits and advantages of CliniQuantum’s algorithm, its advancement toward the analysis of increasingly complex multi-feature configurations and larger biomedical datasets and progressing its development pathway from simulation and validation toward execution on quantum computing hardware. Because such statements deal with future events and are based on SciSparc’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in SciSparc’s Annual Report on Form 20-F, filed with the SEC on April 29, 2026, as amended, and in subsequent filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.
Investor Contact:
[email protected]
Tel: +972-3-6167055
